AR011957A1 - Derivados de dolastatina 15 con funcionalidades carbonilo y heterociclicas en el c-terminal - Google Patents
Derivados de dolastatina 15 con funcionalidades carbonilo y heterociclicas en el c-terminalInfo
- Publication number
- AR011957A1 AR011957A1 ARP980101061A ARP980101061A AR011957A1 AR 011957 A1 AR011957 A1 AR 011957A1 AR P980101061 A ARP980101061 A AR P980101061A AR P980101061 A ARP980101061 A AR P980101061A AR 011957 A1 AR011957 A1 AR 011957A1
- Authority
- AR
- Argentina
- Prior art keywords
- dolastatin
- cyclical
- hetero
- functionalities
- carbonyl
- Prior art date
Links
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical class [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 title 1
- LQKSHSFQQRCAFW-CCVNJFHASA-N [(2s)-1-[(2s)-2-benzyl-3-methoxy-5-oxo-2h-pyrrol-1-yl]-3-methyl-1-oxobutan-2-yl] (2s)-1-[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxyl Chemical class C([C@@H]1N(C(=O)C=C1OC)C(=O)[C@@H](OC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](C(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C)C(C)C)C1=CC=CC=C1 LQKSHSFQQRCAFW-CCVNJFHASA-N 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001371 alpha-amino acids Chemical class 0.000 abstract 1
- 235000008206 alpha-amino acids Nutrition 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invencion se relaciona con nuevos péptidos que son de utilidad como agentes anticancerígenos. Los compuestos de la invencion presentan laformula (I): A - B - D - E - F - G, donde A, B, D y E son residuos de de alfa-aminoácidos.En una realizacion, F es un residuo del ácidoazacicloalcancarboxílico. En esta realizacion, G es un radical monovalente, por ejemlo, un átomo de hidrogeno, un grupo alquilo, un grupo arilo o un grupoheteroarilo. en otra realizacion, F es un grupo azacicloalquilo y G es un grupo heteroarilo conectado a F mediante un enlace carbono-carbono. En otrarealizacion, la invencion incluye un método para tratar el cáncer en un mamífero, como un ser humano, que comprende la administraciona dichomamífero de una cantidad efectiva de un compuesto de formula (I) en una composicion aceptable para uso farmacéutico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/814,577 US5965537A (en) | 1997-03-10 | 1997-03-10 | Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR011957A1 true AR011957A1 (es) | 2000-09-13 |
Family
ID=25215470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980101061A AR011957A1 (es) | 1997-03-10 | 1998-03-10 | Derivados de dolastatina 15 con funcionalidades carbonilo y heterociclicas en el c-terminal |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5965537A (es) |
| EP (1) | EP0981539A1 (es) |
| JP (1) | JP2001518084A (es) |
| KR (1) | KR20000076099A (es) |
| CN (1) | CN1252806A (es) |
| AR (1) | AR011957A1 (es) |
| AU (1) | AU744511B2 (es) |
| BR (1) | BR9808017A (es) |
| CA (1) | CA2297164A1 (es) |
| CO (1) | CO4950525A1 (es) |
| HR (1) | HRP980124A2 (es) |
| HU (1) | HUP0001758A3 (es) |
| IL (1) | IL131596A0 (es) |
| NO (1) | NO994364L (es) |
| TW (1) | TW505657B (es) |
| WO (1) | WO1998040400A1 (es) |
| ZA (1) | ZA981957B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2289549A3 (en) | 1999-10-01 | 2011-06-15 | Immunogen, Inc. | Immunoconjugates for treating cancer |
| CN101307046B (zh) | 2000-10-30 | 2012-08-15 | 詹森药业有限公司 | 三肽酶抑制剂 |
| US6884869B2 (en) * | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US7256257B2 (en) * | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| SI2357006T1 (sl) * | 2002-07-31 | 2016-01-29 | Seattle Genetics, Inc. | Konjugati zdravil in njihova uporaba za zdravljenje raka, avtoimunske bolezni ali infekcijske bolezni |
| DE10240818A1 (de) * | 2002-08-30 | 2004-05-13 | Grünenthal GmbH | Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate |
| FR2856685B1 (fr) * | 2003-06-25 | 2005-09-23 | Merck Sante Sas | Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
| BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
| CA2607940C (en) | 2005-05-18 | 2009-12-15 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| EP2024362A4 (en) | 2006-05-16 | 2012-01-25 | Pharmascience Inc | BINDING COMPOUNDS TO THE IAP BIR DOMAIN |
| SI2176296T1 (sl) | 2007-07-16 | 2012-05-31 | Genentech Inc | Protitelesa proti CD b in imunokonjugati in postopki za uporabo |
| WO2011100403A1 (en) | 2010-02-10 | 2011-08-18 | Immunogen, Inc | Cd20 antibodies and uses thereof |
| US9284350B2 (en) | 2010-02-12 | 2016-03-15 | Pharmascience Inc. | IAP BIR domain binding compounds |
| ES2701076T3 (es) | 2012-11-24 | 2019-02-20 | Hangzhou Dac Biotech Co Ltd | Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células |
| FI3122757T3 (fi) | 2014-02-28 | 2023-10-10 | Hangzhou Dac Biotech Co Ltd | Varautuneita linkkereitä ja niiden konjugointikäyttötapoja |
| WO2016086357A1 (en) * | 2014-12-02 | 2016-06-09 | Merck Sharp & Dohme Corp. | Methyl oxazole orexin receptor antagonists |
| US9987255B2 (en) | 2014-12-19 | 2018-06-05 | Merck Sharp & Dohme Corp. | 5,5-bicyclic oxazole orexin receptor antagonists |
| CN104952808A (zh) * | 2015-06-12 | 2015-09-30 | 广州先艺电子科技有限公司 | 一种预置金锡盖板及其制造方法 |
| EP3307749A4 (en) | 2015-06-15 | 2019-06-19 | Hangzhou Dac Biotech Co., Ltd | HYDROPHILIC LINKER FOR CONJUGATION |
| EP4678240A2 (en) | 2015-07-12 | 2026-01-14 | Hangzhou Dac Biotech Co., Ltd. | Bridge linkers for conjugation of cell-binding molecules |
| US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
| MX2019005583A (es) | 2016-11-14 | 2019-10-21 | Hangzhou Dac Biotech Co Ltd | Vinculantes de conjugacion, conjugados de molecula de union a celulas que contienen los vinculantes, metodos de creacion y usos de dichos conjugados con los vinculantes. |
| CN109776342A (zh) * | 2019-02-26 | 2019-05-21 | 北京大学深圳研究生院 | 顺式β-氨基酸及其衍生物的合成方法 |
| JP7778688B2 (ja) | 2019-10-17 | 2025-12-02 | ジボダン エス エー | Ｔｒｍｐ８モジュレーターとしての置換アザシル |
| US20250281630A1 (en) | 2021-09-03 | 2025-09-11 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
| KR20240095442A (ko) | 2021-11-03 | 2024-06-25 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 항체의 특이적 접합 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816444A (en) * | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
| US4879278A (en) * | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
| US5091368A (en) * | 1990-08-08 | 1992-02-25 | Harbor Branch Oceanographic Institution, Inc. | Biologically active compounds from blue-green algae |
| AU662551B2 (en) * | 1991-08-09 | 1995-09-07 | Teikoku Hormone Mfg. Co., Ltd. | Novel tetrapeptide derivative |
| US5831002A (en) * | 1992-05-20 | 1998-11-03 | Basf Aktiengesellschaft | Antitumor peptides |
| WO1993023424A1 (en) * | 1992-05-20 | 1993-11-25 | Basf Aktiengesellschaft | Derivatives of dolastatin |
| AU679479B2 (en) * | 1992-12-16 | 1997-07-03 | Basf Aktiengesellschaft | Dolostatin analog |
| US5530097A (en) * | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
| US5504191A (en) * | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
| US5554725A (en) * | 1994-09-14 | 1996-09-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis of dolastatin 15 |
| US5807984A (en) * | 1995-11-09 | 1998-09-15 | Basf Aktienegesellschaft | Oligopeptides, the preparation and use thereof |
-
1997
- 1997-03-10 US US08/814,577 patent/US5965537A/en not_active Expired - Fee Related
-
1998
- 1998-03-05 CN CN98803903A patent/CN1252806A/zh active Pending
- 1998-03-05 BR BR9808017-2A patent/BR9808017A/pt not_active IP Right Cessation
- 1998-03-05 WO PCT/US1998/004317 patent/WO1998040400A1/en not_active Ceased
- 1998-03-05 JP JP53963098A patent/JP2001518084A/ja active Pending
- 1998-03-05 HU HU0001758A patent/HUP0001758A3/hu unknown
- 1998-03-05 KR KR1019997008187A patent/KR20000076099A/ko not_active Withdrawn
- 1998-03-05 CA CA002297164A patent/CA2297164A1/en not_active Abandoned
- 1998-03-05 EP EP98910182A patent/EP0981539A1/en not_active Withdrawn
- 1998-03-05 AU AU64482/98A patent/AU744511B2/en not_active Ceased
- 1998-03-05 IL IL13159698A patent/IL131596A0/xx unknown
- 1998-03-09 ZA ZA9801957A patent/ZA981957B/xx unknown
- 1998-03-09 CO CO98012757A patent/CO4950525A1/es unknown
- 1998-03-10 HR HR08/814,577A patent/HRP980124A2/hr not_active Application Discontinuation
- 1998-03-10 TW TW087103515A patent/TW505657B/zh active
- 1998-03-10 AR ARP980101061A patent/AR011957A1/es unknown
-
1999
- 1999-09-09 NO NO994364A patent/NO994364L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2297164A1 (en) | 1998-09-17 |
| JP2001518084A (ja) | 2001-10-09 |
| HUP0001758A3 (en) | 2001-12-28 |
| US5965537A (en) | 1999-10-12 |
| TW505657B (en) | 2002-10-11 |
| ZA981957B (en) | 1999-09-09 |
| AU6448298A (en) | 1998-09-29 |
| CN1252806A (zh) | 2000-05-10 |
| NO994364D0 (no) | 1999-09-09 |
| HUP0001758A2 (hu) | 2001-05-28 |
| WO1998040400A1 (en) | 1998-09-17 |
| CO4950525A1 (es) | 2000-09-01 |
| KR20000076099A (ko) | 2000-12-26 |
| NO994364L (no) | 1999-11-09 |
| HRP980124A2 (en) | 1998-12-31 |
| AU744511B2 (en) | 2002-02-28 |
| EP0981539A1 (en) | 2000-03-01 |
| IL131596A0 (en) | 2001-01-28 |
| BR9808017A (pt) | 2000-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR011957A1 (es) | Derivados de dolastatina 15 con funcionalidades carbonilo y heterociclicas en el c-terminal | |
| AR018501A1 (es) | Derivados de la dolastatina 15 | |
| UY26635A1 (es) | Métodos sinérgicos y composiciones para el tratamiento del cáncer | |
| RU95106649A (ru) | Производные бензимидазола в качестве непептидильных антагонистов рецепторов тахикинина, способ получения, фармацевтическая композиция | |
| ES2038613T3 (es) | Procedimiento para preparar derivados de 4,5,6,7-tetrahidro-1h-imidazo(4,5-c)piridina y analogos de los mismos que tienen actividad antihipertensiva. | |
| ES2039278T3 (es) | Procedimiento para preparar inhibidores de 5-alfa-reductasa de esteroides. | |
| EA200001125A1 (ru) | Гелеобразные фармацевтические композиции | |
| ES2164663T3 (es) | Derivados de paclitaxel unidos a polimeros. | |
| PT662827E (pt) | Metodos de diagnostico e composicoes farmaceuticas a base de proteinas notch e acidos nucleicos | |
| CY1107051T1 (el) | Αντι-διηθητικα και αντι-αγγειογενετικα θραυσματα ουροκινασης και η χρηση τους | |
| DE60029799D1 (de) | Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe | |
| BR0109109A (pt) | Composto, uso do mesmo, processo para prepará-lo, composição farmacêutica, e, método de tratar um estado doentio mediado por ccr5 em mamìferos | |
| ES2187958T3 (es) | Antagonistas de gnrh. | |
| MX9307011A (es) | Derivados hidrosolubles de camptotecina, proceso para su preparacion y composiciones farmaceuticas que los contienen. | |
| KR950701646A (ko) | 폴리펩티드 봄베신 길항제(polypeptide bombestn antagonisis) | |
| BR0208017A (pt) | Combinação compreendendo combretastatina e agentes anticâncer | |
| AR015434A1 (es) | Derivados de eritromicina con puente en 6,9, procedimientos para su preparacion, composicion farmaceutica para tratar infecciones bacterianas que los contiene y su uso para la manufactura de un medicamento | |
| ES2074492T3 (es) | Derivados de acidos biliares, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
| BR0311491A (pt) | Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero | |
| HUP9802206A1 (hu) | Thalidomid intravénás adagolási formája immunológiai megbetegedések gyógyításához | |
| ES2011427T3 (es) | Derivados de la oxima de octahidronaftaleno para la inhibicion de la sintesis del colesterol, procedimientos para su preparacion y composiciones que los contienen. | |
| BR9708854A (pt) | Composto composição farmacêutica processo para estimular a liberação do hormônio do crescimento pela pituitária e para aumentar a taxa e grau de crescimento de animais e uso de um composto | |
| DE60230155D1 (de) | Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung | |
| CO5060499A1 (es) | Metodos y composiciones para el tratamiento de enfermedad de reflujo gastroesofagico | |
| AR035003A1 (es) | Derivados de propanolamina relacionados con acidos biliares, procedimiento para su preparacion, medicamentos conteniendo estos compuestos y su empleo para la preparacion de medicamentos |